Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor.

Leslie J Lipka1

  • 1Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. leslie.lipka@spcorp.com

Cardiovascular Drug Reviews
|December 4, 2003
PubMed
Summary

Ezetimibe combined with statins significantly lowers LDL cholesterol more effectively than statins alone. This combination therapy helps more patients reach cholesterol goals and is well-tolerated, offering a valuable treatment option for hypercholesterolemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vorapaxar in the secondary prevention of atherothrombotic events.

The New England journal of medicine·2012
Same author

Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.

The Lancet. Neurology·2008
Same author

Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2007
Same author

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.

Circulation·2003
Same author

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.

The American journal of cardiology·2003
Same author

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.

Journal of the American College of Cardiology·2002

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Metabolic Disorders

Background:

  • Many patients with coronary heart disease risk do not achieve cholesterol goals with current treatments.
  • Ezetimibe is a novel cholesterol absorption inhibitor with lipid-lowering properties.
  • Preclinical studies suggested ezetimibe enhances statin efficacy.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ezetimibe in combination with statins for hypercholesterolemia.
  • To compare combination therapy to statin monotherapy in achieving lipid goals.
  • To assess ezetimibe's role in various hypercholesterolemia types, including genetic disorders.

Main Methods:

  • Clinical trials involving patients with primary hypercholesterolemia and familial hypercholesterolemia.

Related Experiment Videos

  • Co-administration of ezetimibe with various statins (simvastatin, atorvastatin, pravastatin, lovastatin).
  • Assessment of lipid profiles (LDL-C, HDL-C, triglycerides) and achievement of NCEP-defined goals.

    • Main Results:

    • Ezetimibe plus statin therapy yielded greater reductions in LDL-C compared to statin monotherapy.
    • Combination therapy significantly increased the number of patients achieving LDL-C goals.
    • Ezetimibe added to low-dose statins was as effective as higher statin doses.
    • The combination therapy demonstrated a favorable safety profile comparable to statin monotherapy.

    Conclusions:

    • Ezetimibe and statin combination therapy offers a complementary mechanism for effective lipid lowering.
    • This combination is a valuable treatment option for patients with hypercholesterolemia, including genetic forms.
    • Ezetimibe enhances statin therapy, improving goal attainment and patient outcomes.